ANVS Oct 2024 2.500 put
| Previous close | 0.7500 |
| Open | 0.6500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksKodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
GlobeNewswireAnnovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improveme
ZacksAmicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
